News & Media
VALEO PHARMA PROVIDING GUIDANCE OF RECORD REVENUES FOR THE SECOND QUARTER 2023
Q2-23 revenues to exceed $13.5 million Q2-23 adjusted EBITDA loss to decrease below $2.0 million Q2-23 operating expenses to remain in line with prior quarters ...
Latest News
VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS AND COMMITTEE APPOINTMENTS
MONTREAL, QUEBEC , April 28, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF,...
VALEO PHARMA TO PRESENT AT THE 2023 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE
MONTREAL, QUEBEC , April 19, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF,...
VALEO PHARMA REPORTS RECORD QUARTERLY REVENUES FOR THE FIRST QUARTER 2023
• Fifth consecutive quarter of revenue growth at $13.2 million in Q1-23, up...
VALEO PHARMA TO HOST FIRST QUARTER 2023 RESULTS CONFERENCE CALL / WEBCAST
MONTREAL, QUEBEC , March 9, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF,...
VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ONSTRYV® IN QUEBEC
Quebec public reimbursement coverage to facilitate and expand medication...
VALEO PHARMA REPORTS RECORD QUARTERLY AND ANNUAL REVENUES FOR THE FOURTH QUARTER AND THE FISCAL YEAR 2022
Record quarterly revenues of $12.7 million in Q4-22, up 274% over Q4-21 Record...
VALEO PHARMA ANNOUNCES FILING OF A NEW DRUG SUBMISSION-COVID 19 WITH HEALTH CANADA FOR SABIZABULIN FOR THE TREATMENT OF HOSPITALIZED COVID-19 PATIENTS
In the final analysis of the Phase 3 cinical study conducted by Veru Inc.,...
VALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2022 RESULTS CONFERENCE CALL / WEBCAST
MONTREAL, QUEBEC , January 25, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB:...
Past Press Releases
hidden
2022
2021
2020